ABSTRACT
INTRODUCTION
Fetal growth restriction (FGR) is one of the most clinically important obstetric conditions, associated with an increased risk of mortality and morbidity in the perinatal period 1, 2 , and prenatal identification results in a reduction of adverse perinatal outcomes and stillbirth 3 -5 . First-trimester prediction of FGR is one of the main goals of fetal medicine research, because at this point in pregnancy prophylactic strategies with administration of aspirin can potentially halve the incidence of the condition 6 . However, the prediction reported for FGR so far 7 -15 has not been as good as that for pre-eclampsia (PE), with detection rates (DRs) ranging from 12% 7 to 47% 12 for a 10% false-positive rate (FPR). This poor performance may partially reflect some heterogeneity of case definitions, and particularly the fact that most studies used a 'small-for-dates newborn' as a surrogate for FGR. In a recent study 16 we demonstrated that, when a strict definition of FGR is used and angiogenic factors are included in the algorithm, the first-trimester prediction improved substantially, reaching a DR of 67%.
Two distinct clinical forms of FGR can be distinguished in relation to gestational age (GA). Early-onset FGR is a severe disorder with the typical pattern of escalating deterioration often requiring preterm delivery 17 -19 , whereas late-onset FGR is much more common than the early form and is milder, allowing delivery at term and showing a different deterioration pattern from that of early FGR, but nonetheless constitutes a major contributing factor to adverse perinatal outcome 4 . These two clinical forms of FGR also differ in their predictability. Previous studies 7, 10, 12, 14, 15 have reported a higher DR for early-onset FGR (38% 10 -73% 12 for 10% FPR), particularly due to its strong association with PE, in comparison with late-onset FGR (23% 15 -51% 14 for 10% FPR). We speculated that the prediction of early and late FGR could be improved by using specific algorithms for each clinical form. The aim of this study was to develop optimal first-trimester screening models for early and late FGR by combining maternal characteristics and biophysical parameters with measurements of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), which are known to have predictive capacity for placental disorders early in pregnancy 16, 20, 21 .
SUBJECTS AND METHODS

Study population
This was a nested case-control study within a large prospective cohort of consecutive and unselected singleton pregnancies referred for routine first-trimester screening for aneuploidies (8 + 0 to 13 + 6 weeks' gestation) at the Department of Maternal-Fetal Medicine at Hospital Clinic, Barcelona. Blood samples to evaluate biomarkers for screening for aneuploidies were taken from each patient at 8 + 0 to 11 + 6 weeks' gestation. At 11 + 0 to 13 + 6 weeks' gestation each patient underwent a first-trimester visit that included recording of maternal characteristics and medical history, measurement of maternal weight and height, ultrasound examination of fetal anatomy, screening for aneuploidies and measurement of crown-rump length for assessment of GA 22 . The third-trimester visit, at 30 + 0 to 33 + 6 weeks' gestation, included ultrasonography to assess fetal growth based on the estimated fetal weight (EFW) 23 . If EFW was < 10 th percentile adjusted by GA and gender, according to local standards 24 , the patient was admitted to the outpatient clinic for specific follow-up. Our ethics committee approved the study protocol and each patient provided written informed consent. Between May 2007 and March 2012, 9970 women underwent examination. Of these, 803 (8.1%) were excluded for one or more reasons: missing outcome data (n = 607), major fetal defects or chromosomal abnormality (n = 39), miscarriage or fetal death before 24 weeks' gestation (n = 105) and termination of pregnancy without a medical indication (n = 52). After exclusions, 9167 cases remained.
Outcome measures
Small-for-gestational-age (SGA) newborns were defined as those with a birth weight (BW) < 10 th percentile, adjusted by GA at delivery and gender 24 . Among them, FGR fetuses were defined as those with an EFW < 10 th percentile confirmed at delivery according to local standards 24 plus an abnormal cerebroplacental ratio 25 and/or uterine artery (UtA) Doppler 26 , or a BW < 3 rd percentile 19 , irrespective of the Doppler status before delivery. FGR cases were then subdivided according to GA at delivery, using as a cut-off the 34 th week of gestation (early FGR < 34 weeks, late FGR ≥ 34 weeks) 17 . PE was defined according to the International Society for the Study of Hypertension in Pregnancy guidelines 27 : two recordings of systolic blood pressure (BP) ≥ 140 mmHg or diastolic BP ≥ 90 mmHg at least 4 h apart in a previously normotensive woman after 20 weeks' gestation and proteinuria ≥ 300 mg/24 h. For women with chronic hypertension (hypertension before conception or ); a-priori risk and biophysical parameters (blood pressure and uterine artery Doppler) ( ); a-priori risk, biophysical parameters and ratio of the angiogenic factors (soluble fms-like tyrosine kinase-1 : placental growth factor) ( ).
at the initial first-trimester visit), superimposed PE was defined as the same level of proteinuria developing after 20 weeks' gestation. Early PE was defined as PE requiring delivery before 34 weeks' gestation, whereas late PE was defined as delivery after 34 weeks.
Doppler measurements
Fetal biometry and prenatal Doppler ultrasound examinations were performed by experienced technicians using a Siemens Sonoline Antares (Siemens Medical Systems, Malvern, PA, USA) or GE Voluson E8 (GE Medical Systems, Zipf, Austria) ultrasound machine equipped with a 6-12-MHz linear curved-array transducer. The technicians were blinded to the first-trimester screening results. The evaluated variables included fetal biometry with EFW and Doppler evaluation of the pulsatility index (PI) in the umbilical, fetal middle cerebral artery and ductus venosus, and mean PI of both UtAs. Cerebroplacental ratio was calculated as the middle cerebral artery PI divided by the umbilical artery PI 25 . Follow-up of these pregnancies was based on a specific hospital protocol, reported elsewhere 18 .
Predictive variables
Maternal characteristics
Maternal characteristics were recorded prospectively at booking via a questionnaire. The recorded variables were: maternal age, ethnicity (white, black, Latin-American, Asian or other), nulliparity (no previous delivery after 24 weeks' gestation), smoking during pregnancy (yes or no), conception method (spontaneous or via assisted reproductive technologies), medical history (chronic hypertension, diabetes mellitus, renal disease, autoimmune disease, or congenital or acquired thrombophilic conditions) and obstetric history (previous pregnancy with FGR, PE or stillbirth). Adverse obstetric history was defined as previous FGR, PE and/or stillbirth. Data on pregnancy and neonatal outcomes were obtained from the database of Hospital Clinic, Barcelona.
Biophysical parameters
Maternal BP was measured using an automatic, calibrated OMRON M6 Confort (OMRON Corporation, Kyoto, Japan) device at the time of the first-trimester ultrasound examination (11 + 0 to 13 + 6 weeks' gestation). BP was measured while the woman was seated, after a 5-min rest. Mean arterial pressure (MAP) was calculated as: diastolic BP + (systolic BP -diastolic BP)/3. AUC, area under the receiver-operating characteristics curve; DR, detection rate; FPR, false-positive rate; MAP, mean arterial pressure; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; UtA, uterine artery. UtA Doppler assessment was performed transvaginally during the first trimester, as described previously 28 . The PI of both UtAs was measured automatically, and the mean UtA-PI was calculated.
Blood samples and biochemical analysis
Venous blood samples were drawn from each woman at 8 + 0 to 11 + 6 weeks' gestation (mean 10.0 (SD 0.93) weeks). After collection in two distinct tubes, one with EDTA, they were processed within 1 h. Serum and plasma were separated by centrifugation at 3000 rpm for 10 min at 4
• C, and samples were stored immediately at −80 • C until assayed. Plasma concentrations of pregnancy-associated plasma protein-A (PAPP-A) and free β-human chorionic gonadotropin (fβ-hCG) were measured using the AUTODELFIA XPRESS analyzer (Perkin-Elmer Life Science, Turku, Finland). These values were converted to multiples of the expected median (MoM), which were corrected for crown-rump length, maternal age, ethnicity, body mass index and smoking and diabetes status, according to local references 29 . In all 462 FGR cases and in 702 unaffected women, PlGF and sFlt-1 levels in maternal serum were measured according to the manufacturer's instructions using the corresponding ELISA kit (R&D Systems Europe Ltd, Abingdon, UK). Samples were assigned randomly to each plate, and cases and controls were always run in parallel. For sFlt-1 measurements, serum samples were diluted 1/10 or 1/5, so readings fit within the standard curve. For PlGF, samples were tested undiluted. Grossly hemolyzed samples were excluded from the assays. The intra-assay and interassay precisions were calculated by running an internal control with the samples. This control was prepared from 30 randomly selected samples, pooled and stored at −80
• C. One aliquot was used per assay. The mean coefficients of variation for the intra-assay precision for sFlt-1 and PlGF were 5% and 6%, respectively, and the mean interassay precision was 11% for both. The concentration of angiogenic factors in the samples was determined by four-parameter logistic regression fit of the standard; the regression coefficient of the curves was never below 0.99.
Statistical analysis
ANOVA with Bonferroni post-hoc test and Pearson chi-square test were used for univariable comparisons of quantitative and qualitative variables, respectively, among groups. A binomial distribution model was used to determine the 95% CI of proportions. Several steps were used to develop specific predictive algorithms for early and late FGR. First, for each patient in the FGR group (early and late separately) and unaffected groups, the a-priori risk for FGR was calculated using logistic regression analysis with forward stepwise elimination to determine which factors among maternal characteristics and obstetric history significantly contributed to predicting FGR. Second, the MAP, mean UtA-PI, PlGF, sFlt-1 and sFlt-1 : PlGF ratio (sFlt-1 divided by PlGF) were log 10 -transformed to make their distribution normal. Third, the log 10 MAP and log 10 mean UtA-PI measurements were converted into MoMs after adjustment for characteristics as reported elsewhere 16 . Fourth, logistic regression analysis was used to determine the significance of the association between biomarkers in the FGR and unaffected groups. Fifth, as PlGF and sFlt-1 were not measured in every woman, the mean and SD of the Gaussian distribution in unaffected women were used to estimate the values in the rest of the screened controls, according to standard methodology recommended for nested case-control studies 30 . Sixth, the predictive performance for early and late FGR by a-priori risk (log 10 ), MoM MAP, MoM mean UtA-PI, MoM PAPP-A, MoM fβ-hCG, log 10 PlGF, log 10 sFlt-1 and log 10 sFlt-1 : PlGF ratio, individually and in various combinations, was determined by receiver-operating characteristics (ROC) curve analysis, in which binomial smoothing was applied. Paired ROC curves were compared by the DeLong method 31 . Seventh, algorithms for FGR were applied to the whole population, and estimated DRs were calculated for different FPR cut-offs. Eighth, the predictive performance of the fitted algorithms was calculated in FGR subgroups with or without PE.
In all regression models, stepwise algorithms were performed to select variables at a 0.05 P-value cut-off. Goodness-of-fit models were assessed by calculating Nagelkerke's R 2 . IBM SPSS 19.0 (New York, NY, USA) and R version 2.15.1 (The R Foundation for Statistical Computing, Vienna, Austria) with the package pROC version 1.7.2 were used for statistical analyses and graph construction.
RESULTS
Of the 9167 neonates, 996 (10.9%) were SGA and 479 (5.2%) were growth restricted. Angiogenic factor levels were not available in 17 growth-restricted cases, which were excluded from the final analysis, leaving a total of 9150 newborns of which 462 were growth restricted. Of these, 59 (0.6% of the cohort, 12.8% of growth-restricted fetuses) met the criteria for early FGR and 403 (4.4% of the cohort, 87.2% of growth-restricted fetuses) for late FGR. Table 1 shows the epidemiological and clinical characteristics of the study groups. Biophysical and biochemical variables during first-trimester evaluation are summarized in Table 2 . Maternal and neonatal outcomes are shown in Table 3 .
On univariable analyses, MAP MoM and mean UtA-PI MoM were significantly greater in the early FGR (P < 0.001) and late FGR (P < 0.001) groups, compared with unaffected cases. PAPP-A MoM and fβ-hCG Table 7 Predictive performance of screening for late fetal growth restriction (FGR) with or without pre-eclampsia (PE)
DR (% (95%CI)) for FPR of:
Parameter AUC (95% CI) 5% 10%
Late FGR with PE (n = 47, 11.7%) A-priori risk (log 10 AUC, area under the receiver-operating characteristics curve; DR, detection rate; FPR, false-positive rate; MAP, mean arterial pressure; NA, not available; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; UtA, uterine artery. Only the first author of each study is listed. *Early and late FGR were subdivided with delivery cut-off of 34 weeks. †Early and late FGR were subdivided with delivery cut-off of 37 weeks. ADAM12, ADAM metallopepsidase domain 12; A-priori, maternal a-priori risk; CRL, crown-rump length; DR, detection rate; FPR, false-positive rate; fβ-hCG, free-β-human chorionic gonadotropin; MAP, mean arterial pressure; NT, nuchal translucency; PAPP-A, pregnancy-associated plasma protein-A; PlGF, placental growth factor; PP13, placental protein 13; sFlt-1, soluble fms-like tyrosine kinase-1; UtA, uterine artery.
MoM were similar for the two FGR groups. PlGF (log 10 -transformed) was significantly lower in the early FGR group compared with the late FGR and unaffected groups (P < 0.001), and in the late FGR group compared with unaffected cases (P < 0.001). By contrast, log 10 sFlt-1 was significantly higher in early and late growth-restricted cases compared with controls (P < 0.001 for both FGR groups). Similarly, the log 10 sFlt-1 : PlGF ratio was significantly higher in both FGR groups compared with the unaffected group (P < 0.001), and in the early FGR group compared with the late cases (P < 0.001).
Predicting early FGR
The following models best fit the prediction for early FGR (a-priori and a-posteriori risk = e y /(1 + e y )). The DRs for early FGR at different FPRs are presented in Table 4 . ROC curves of the multivariable model are shown in Figure 1 . In the early-onset FGR group, 38 women (64.4%) had PE. Table 5 provides DRs for early FGR with or without PE for different FPRs.
Predicting late FGR
The following models best fit the prediction for late FGR (a-priori and a-posteriori risk = e y /(1 + e y )). The DRs for late FGR at different FPRs are presented in Table 6 . ROC curves of the multivariable model are shown in Figure 2 . In the late-onset FGR group, 47 (11.7%) women had PE. Table 7 presents DRs for late FGR with or without PE for different FPRs.
DISCUSSION
Our findings suggest that first-trimester screening for FGR is performed more effectively using separate algorithms for early-and late-onset forms. A combination of several maternal characteristics, biophysical parameters (BP and UtA Doppler) and angiogenic factor levels (PlGF and sFlt-1) achieved DRs for early and late FGR of 86% and 66%, respectively, with a FPR of 10%.
This study confirmed our previous findings 15, 16 that specific screening in the first trimester for FGR is feasible, particularly for early-onset FGR, which represents the most severe form of growth restriction and can also be partially prevented through aspirin administration 6 . Furthermore, this study substantially improved our previous algorithms for the prediction of early-and late-onset SGA 15 , achieving the highest reported DRs for each form of FGR, as shown in Table 8 7 -15 . This may be attributed to the stringent definition of FGR used for our study population, including abnormal Doppler parameters or a BW < 3 rd percentile, reflecting placental insufficiency, and to the inclusion of angiogenic factors. As we have already demonstrated for the prediction of overall FGR 16 , biophysical parameters added little to epidemiological factors, whereas the sFlt-1 : PlGF ratio improved the DRs by 27% for early FGR and 24% for late-onset forms, highlighting the potential role of these biomarkers for predicting growth restriction.
Among the studies examining FGR prediction, only some have involved large cohorts (Table 8 ) and the majority used SGA as the outcome and not a prenatal definition of FGR. Only a few have separately addressed early and late FGR 7, 10, 12, 14, 15 , using 34 weeks' gestation 7, 15 or 37 weeks' gestation 10, 12, 14 at delivery as a cut-off to differentiate the subgroups. Early FGR represents one third of FGR cases, and its association with PE is very important, not only because more than half of cases are associated with this condition 18 , but also because in such cases DR is very high (almost 95% with a 10% FPR). Nevertheless, the majority of growth-restricted fetuses belonged to the late-onset group with a lower association with PE 17 -19 . First-trimester screening performance is poorer for late FGR, but PlGF and sFlt-1 increased the DRs to an acceptable level. It is of interest that late-onset cases were not influenced by PE, as DR remained the same (70% vs 64% with or without PE, respectively). Studies from the Harris Birthright Research Centre for Fetal Medicine also reported an acceptable DR for early FGR cases, defined with BW < 5 th centile without PE, whereas DR for late FGR was worse; however, they used the 37 th week of gestation as a cut-off 12, 14 . For the prediction of early FGR we found a relatively greater improvement in DR with the addition of angiogenic factors in normotensive (from 23.8% to 71.4%) than in pre-eclamptic (from 42.1% to 94.7%) women. This may be due to the fact that in women destined to develop PE the defective trophoblastic invasion is well captured by UtA Doppler, whereas in normotensive women other mechanisms (such as inflammation or ischemia) not well reflected in this vessel play a role.
For the prediction of late FGR the improvement in DR by adding angiogenic factors was greater in women subsequently developing PE. It could be speculated that cases of late PE/FGR are simply at the end of the spectrum of the gestational-age onset of cases with angiogenic misbalances already present early in pregnancy.
The strengths of our study are the inclusion of two angiogenic factors that are promising biomarkers for predicting not only PE but also FGR, and that the screening was applied to those cases clearly defined as growth restricted 19 and not to SGA babies. We acknowledge as a limitation of the study that the sample size may be insufficient for some of the analyzed subgroups. Additionally, on average we drew blood samples earlier than in previous studies (Table 8 ). It could be speculated that this may have limited their predictive value, as it is likely that markers of defective trophoblastic invasion become more abnormal as pregnancy progresses.
As these two FGR subgroups differ not only in terms of clinical characteristics but also in their predictability, we believe that it is better to use a specific algorithm for each form in the first trimester, instead of a model for the prediction of overall FGR 16 . This study provides two specific risk algorithms for early and late FGR, combining maternal characteristics, BP, UtA Doppler, PlGF and sFlt-1. These models, although showing an improved performance in the presence of PE, remain useful in normotensive cases. Early estimation of patient-specific risks for FGR could potentially improve pregnancy outcome by allowing targeted antenatal care. Furthermore, increased awareness may increase the detection of a growth-restricted fetus.
